Here is an in-depth response from Russell Higgins, MD, a colleague of John Olson, MD, and current chair of the Coagulation Resource Committee of the College of American Pathologists (CAP) to Dee McMichael’s March 2 question about monitoring factor activity in the presence of an inhibitor:
From Dr; Olson: “We discussed this at our weekly coagulation consensus conference this morning. It reflects our thoughts on the questions. I believe that the CLSI document on assays recommends that dilution up to 1:160, but, as pointed out by Dr. Higgins, I’m not aware of data behind this recommendation. I believe that it was a consensus opinion.”
No comments here.